NASDAQ NMS - GLOBAL MARKET · PHAT
+2.62% · +$0.2200 · Vol 2.3M
Market closed · last close 4:00 PM ET · price as of 18:45:15 ET
Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc

Pharmaceuticals
$8.61
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
PHAT
Phathom Pharmaceuticals Inc
Fri Aug 7 · market closed · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

57/ 100
Veridion Score
NEUTRAL · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Fri Aug 7 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is PHAT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading PHAT catalysts
About Phathom Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2019
Employees
371
Country
US

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$8.48
Day high
$8.61
Day low
$8.30
Previous close
$8.39
52W high
$18.08
-52.38% from high
52W low
$8.23
4% of range
Market cap
$678.8M
EPS
$-2.9800
Beta
-0.33
Shares out
80.9M
Volume
2.3M
1.51× rel vol
Avg volume
1.5M
VWAP
$8.45
Price history computed in-house
1W
-1.60%
1M
-29.19%
3M
-29.19%
1Y
-11.60%
YTD
-48.10%
SMA 50 $10.52 · below
SMA 200 $12.54 · below
52W position 4%

PHAT overview

Veridion Score
57
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around PHAT.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading PHAT Form 4 filings
Public disclosures

Congress activity in PHAT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for PHAT in the cached public ledger.

Federal contracts

PHAT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PHAT in this window.
Lobbying spend

PHAT lobbying filings, year to date.

Registered lobbying filings matched to Phathom Pharmaceuticals Inc.

$45.0K
Refresh interval: 12hSource: LDA disclosure filings
Health Issues
Filing
$15.0K
PHATHOM PHARMACEUTICALS

JEFFREY J. KIMBELL & ASSOCIATES, INC.

Jul 20, 2026
Filing
$15.0K
PHATHOM PHARMACEUTICALS

JEFFREY J. KIMBELL & ASSOCIATES, INC.

Apr 20, 2026
Filing
$15.0K
PHATHOM PHARMACEUTICALS

JEFFREY J. KIMBELL & ASSOCIATES, INC.

Jan 20, 2026
Loading news for PHAT
Analyst ratings
Sovereign unlock shows live analyst consensus for PHAT.
Options
Sovereign unlock shows live options positioning for PHAT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.